Guardant Health, Inc. (GH)

Market Cap	3.79B
Revenue (ttm)	692.26M
Net Income (ttm)	-512.41M
Shares Out	123.55M
EPS (ttm)	-4.22
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,556,001
Open	30.66
Previous Close	30.68
Day's Range	30.14 - 30.75
52-Week Range	15.81 - 37.04
Beta	1.11
Analysts	Strong Buy
Price Target	39.07 (+27.35%)
Earnings Date	Nov 6, 2024

About GH

Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for adv...

• Industry: Diagnostics & Research
• Sector: Healthcare
• IPO Date: Oct 4, 2018
• Employees: 1,779
• Stock Exchange: NASDAQ
• Ticker Symbol: GH
• Website: https://guardanthealth.com

Financial Performance

In 2023, Guardant Health's revenue was $563.95 million, an increase of 25.45% compared to the previous year's $449.54 million. Losses were -$479.45 million, -26.76% less than in 2022.

Analyst Forecast

According to 16 analysts, the average rating for GH stock is "Strong Buy." The 12-month stock price forecast is $39.07, which is an increase of 27.35% from the latest price.

Price Target

$39.07

(27.35% upside)

Analyst Consensus: Strong Buy